AR072734A1 - Composiciones farmaceuticas basadas en antagonistas del receptor de quinina b2 y corticosteroides y su uso - Google Patents
Composiciones farmaceuticas basadas en antagonistas del receptor de quinina b2 y corticosteroides y su usoInfo
- Publication number
- AR072734A1 AR072734A1 ARP090102611A ARP090102611A AR072734A1 AR 072734 A1 AR072734 A1 AR 072734A1 AR P090102611 A ARP090102611 A AR P090102611A AR P090102611 A ARP090102611 A AR P090102611A AR 072734 A1 AR072734 A1 AR 072734A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- arg
- acid
- oxymethyl
- dichloro
- Prior art date
Links
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 title abstract 9
- 239000003246 corticosteroid Substances 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 239000005557 antagonist Substances 0.000 title 1
- 229960001334 corticosteroids Drugs 0.000 title 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 4
- 235000001258 Cinchona calisaya Nutrition 0.000 abstract 4
- -1 Fluocortone Chemical compound 0.000 abstract 4
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 abstract 4
- 229960000948 quinine Drugs 0.000 abstract 4
- 239000002464 receptor antagonist Substances 0.000 abstract 4
- 229940044551 receptor antagonist Drugs 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 abstract 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 abstract 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 abstract 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- XUHBBTKJWIBQMY-MHZLTWQESA-N Anatibant Chemical compound O=C([C@@H]1CCCN1S(=O)(=O)C=1C=CC(Cl)=C(C=1Cl)COC1=CC=CC2=C(C)C=C(N=C21)C)NCCCNC(=O)C1=CC=C(C(N)=N)C=C1 XUHBBTKJWIBQMY-MHZLTWQESA-N 0.000 abstract 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 abstract 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 abstract 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 abstract 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 abstract 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 abstract 1
- MKPDWECBUAZOHP-AFYJWTTESA-N Paramethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O MKPDWECBUAZOHP-AFYJWTTESA-N 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 229950004248 anatibant Drugs 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 229940092705 beclomethasone Drugs 0.000 abstract 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 abstract 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 abstract 1
- 229960002537 betamethasone Drugs 0.000 abstract 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 abstract 1
- 229960004436 budesonide Drugs 0.000 abstract 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 229960004544 cortisone Drugs 0.000 abstract 1
- 229960003957 dexamethasone Drugs 0.000 abstract 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 abstract 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 229960001484 edetic acid Drugs 0.000 abstract 1
- 230000002500 effect on skin Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229960003469 flumetasone Drugs 0.000 abstract 1
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 abstract 1
- 229960000676 flunisolide Drugs 0.000 abstract 1
- 229960002714 fluticasone Drugs 0.000 abstract 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 abstract 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 abstract 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 abstract 1
- 229960001810 meprednisone Drugs 0.000 abstract 1
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 abstract 1
- 229940098779 methanesulfonic acid Drugs 0.000 abstract 1
- 229960004584 methylprednisolone Drugs 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 abstract 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229960005205 prednisolone Drugs 0.000 abstract 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 abstract 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 abstract 1
- 125000001453 quaternary ammonium group Chemical group 0.000 abstract 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 abstract 1
- 239000001384 succinic acid Substances 0.000 abstract 1
- 229960005137 succinic acid Drugs 0.000 abstract 1
- 229960005294 triamcinolone Drugs 0.000 abstract 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 abstract 1
- 229940005605 valeric acid Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Composiciones farmacéuticas que contienen, como ingredientes activos, una mezcla de un corticosteroide y un antagonista del receptor de quinina B2. Se ha comprobado que dichas composiciones son particularmente eficaces, en especial en el tratamiento de trastornos inflamatorios, tales como el asma, de trastornos oftalmologicos o dérmicos, y sobre todo, de trastornos relacionados con las articulaciones y con la artritis. Reivindicacion 1: Una composicion farmacéutica caracterizada porque comprende, como ingredientes activos, un corticosteroide y un antagonista del receptor de quinina B2, junto con vehículos y excipientes farmacéuticamente aceptables, donde a) el corticosteroide, ya sea natural o sintético, se selecciona entre Cortisona, Hidrocortisona, Beclometasona, Betametasona, Budesonide, Dexametasona, Flumetasona, Flunisolide, Fluocortona, Fluticasona, Metilprednisolona, Metilprednisona. Parametasona, Prednisolona, Triamcinolona, opcionalmente en forma de un éster con ácido acético, benzoico, caproico, succínico, fosforico, propionico o valérico, o en forma de acetonida: b) el antagonista del receptor de quinina B2 se selecciona entre -H-D-Arg-Arg-Pro-Hyp-Gly-IgI-Ser-D-F5F-IgI-Arg-OH; -H-Arg-Arg-Pro-Hyp-Gly-IgI-Ser-D-lgI-Oic-Arg-OH; -H-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg-OH (lcatibant): -4-[2-[([[3-(3-bromo-2-metil-imidazo[1,2-a]piridina-8-il oximetil)-2,4-dicloro-fenil]-metil-carbamil]-metil)-carbamil]-vinil]-N,N-dimetil-benzamida;-3-(6-acetilamino-piridin-3-iI)-N-([[2,4-dicloro-3-(2-metil-quinolin 8-il oximetil)-fenil]-metil-carbamil]-metil)-acrilamida; -[3-(4-carbamidil-benzilamino)-propil]-amida de ácido 1-[2,4 dicloro-3-(2,4-dimetil-quinolin-8-il oximetil)-benceno sulfonil]-pirrolidina-2-carboxílico (Anatibant); Bradizide; -4-(4-[1-[2,4-dicloro-3-(2,4-dimetil-quinolin-8-il oximetil)-bencensulfonil]-pirrolidina-2-carbonil]piperazina-1-carbonil)-benzamidina; -2-[5-(4-ciano-benzil)-1-metil-1H-pirrol-2-iI]-N-[2,4-dicloro-3-(2-metil-quinolina-8-il oximetil)-fenil]-N-metil-acetamida: -un compuesto de formula general (1) donde R es hidrogeno o metilo: W representa un enlace simple o un átomo de oxigeno; n = 3, 4; X es hidrogeno o un grupo amina -NR1R2, donde R1 y R2 son independientemente hidrogeno o un grupo seleccionado entre metilo, etilo, n-propilo, isopropilo; Y es amonio cuaternario -NR3R4R5, donde R3, R4, R5, son independientemente metilo, etilo, n-propilo, isopropilo, butilo, isobutilo, n pentilo; sales, enantiomeros y mezclas enantioméricas farmacéuticamente aceptables de éstos. Reivindicacion 3: Una composicion farmacéutica de acuerdo con la reivindicacion 2, caracterizada porque dicho antagonista del receptor de quinina B2 es, de acuerdo con la formula general (1), el compuesto (4-(S)-amino-5-(4-{4-[2,4-dicloro-3-(2,4-dimetil-quinolin-8-iloximetil)-bencensulfonilamino]-tetrahidro-piran-4-carbonil}-piperazin-1-il)-5-oxo-pentil]-trimetil-amonio, en forma de una sal con ácido clorhídrico, acético, sulfurico, trifluoroacético, metanosulfonico, succínico o edético, preferiblemente en forma del biclorhidrato del cloruro (MEN16132).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI2008A001264A IT1391236B1 (it) | 2008-07-11 | 2008-07-11 | Composizioni farmaceutiche a base di antagonisti del recettore b2 delle chinine e corticosteroidi e loro uso |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072734A1 true AR072734A1 (es) | 2010-09-15 |
Family
ID=40466843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102611A AR072734A1 (es) | 2008-07-11 | 2009-07-08 | Composiciones farmaceuticas basadas en antagonistas del receptor de quinina b2 y corticosteroides y su uso |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US8476276B2 (es) |
| EP (1) | EP2303268B1 (es) |
| JP (1) | JP5791501B2 (es) |
| KR (1) | KR101656324B1 (es) |
| CN (1) | CN102088975B (es) |
| AP (1) | AP2803A (es) |
| AR (1) | AR072734A1 (es) |
| AU (1) | AU2009267416B2 (es) |
| BR (1) | BRPI0915866A2 (es) |
| CA (1) | CA2730420A1 (es) |
| CO (1) | CO6341556A2 (es) |
| CR (1) | CR20110021A (es) |
| CY (1) | CY1112900T1 (es) |
| DK (1) | DK2303268T3 (es) |
| EA (1) | EA019903B1 (es) |
| EC (1) | ECSP11010752A (es) |
| ES (1) | ES2389872T3 (es) |
| GE (1) | GEP20135792B (es) |
| HK (1) | HK1158547A1 (es) |
| HN (1) | HN2011000089A (es) |
| HR (1) | HRP20120678T1 (es) |
| IL (1) | IL210554A0 (es) |
| IT (1) | IT1391236B1 (es) |
| MA (1) | MA32542B1 (es) |
| MX (1) | MX2011000350A (es) |
| MY (1) | MY150477A (es) |
| NI (1) | NI201100014A (es) |
| NZ (1) | NZ590427A (es) |
| PL (1) | PL2303268T3 (es) |
| PT (1) | PT2303268E (es) |
| RS (1) | RS52418B (es) |
| SI (1) | SI2303268T1 (es) |
| TW (1) | TWI499419B (es) |
| UA (1) | UA100060C2 (es) |
| WO (1) | WO2010003601A1 (es) |
| ZA (1) | ZA201100287B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120190653A1 (en) * | 2011-01-20 | 2012-07-26 | Dow Pharmaceutical Sciences, Inc. | Therapeutic eye drop comprising doxycycline and a stabilizer |
| AU2014244592A1 (en) * | 2013-03-14 | 2015-09-24 | Shire Human Genetic Therapies, Inc. | Methods of treating B2-bradykinin receptor mediated angioedema |
| CN104072585A (zh) * | 2014-07-21 | 2014-10-01 | 成都圣诺生物科技股份有限公司 | 一种合成艾替班特的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2451602A1 (en) * | 2001-06-26 | 2003-01-03 | Metaphore Pharmaceuticals, Inc. | Combination therapy of an sodm and a corticosteroid for prevention and/or treatment of inflammatory disease |
| ITMI20021247A1 (it) * | 2002-06-07 | 2003-12-09 | Menarini Ricerche Spa | Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche |
| DE10304994A1 (de) * | 2003-02-07 | 2004-09-02 | Aventis Pharma Deutschland Gmbh | Die Verwendung von Antagonisten des Bradykinin-B2 Rezeptors zur Behandlung von Osteoarthrose |
| ITMI20041963A1 (it) * | 2004-10-15 | 2005-01-15 | Luso Farmaco Inst | "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche" |
| EP1741444A1 (en) * | 2005-07-05 | 2007-01-10 | Jerini AG | Kinin antagonists for treating bladder dysfunction |
| EP1894559A1 (en) * | 2006-09-01 | 2008-03-05 | PARI Pharma GmbH | Means to solubilise steroids for inhalation |
-
2008
- 2008-07-11 IT ITMI2008A001264A patent/IT1391236B1/it active
-
2009
- 2009-07-03 MX MX2011000350A patent/MX2011000350A/es active IP Right Grant
- 2009-07-03 MY MYPI20110133 patent/MY150477A/en unknown
- 2009-07-03 KR KR1020117000761A patent/KR101656324B1/ko active IP Right Grant
- 2009-07-03 DK DK09793880.7T patent/DK2303268T3/da active
- 2009-07-03 AU AU2009267416A patent/AU2009267416B2/en not_active Ceased
- 2009-07-03 AP AP2011005572A patent/AP2803A/xx active
- 2009-07-03 WO PCT/EP2009/004847 patent/WO2010003601A1/en active Application Filing
- 2009-07-03 BR BRPI0915866A patent/BRPI0915866A2/pt not_active IP Right Cessation
- 2009-07-03 PT PT09793880T patent/PT2303268E/pt unknown
- 2009-07-03 SI SI200930330T patent/SI2303268T1/sl unknown
- 2009-07-03 NZ NZ590427A patent/NZ590427A/xx not_active IP Right Cessation
- 2009-07-03 EP EP09793880A patent/EP2303268B1/en active Active
- 2009-07-03 PL PL09793880T patent/PL2303268T3/pl unknown
- 2009-07-03 EA EA201100013A patent/EA019903B1/ru not_active IP Right Cessation
- 2009-07-03 RS RS20120360A patent/RS52418B/en unknown
- 2009-07-03 UA UAA201100312A patent/UA100060C2/uk unknown
- 2009-07-03 GE GEAP200912055A patent/GEP20135792B/en unknown
- 2009-07-03 JP JP2011517005A patent/JP5791501B2/ja not_active Expired - Fee Related
- 2009-07-03 CA CA2730420A patent/CA2730420A1/en not_active Abandoned
- 2009-07-03 ES ES09793880T patent/ES2389872T3/es active Active
- 2009-07-03 US US13/003,608 patent/US8476276B2/en not_active Expired - Fee Related
- 2009-07-03 CN CN2009801267958A patent/CN102088975B/zh not_active Expired - Fee Related
- 2009-07-08 AR ARP090102611A patent/AR072734A1/es unknown
- 2009-07-09 TW TW098123207A patent/TWI499419B/zh not_active IP Right Cessation
-
2011
- 2011-01-10 EC EC2011010752A patent/ECSP11010752A/es unknown
- 2011-01-10 NI NI201100014A patent/NI201100014A/es unknown
- 2011-01-10 HN HN2011000089A patent/HN2011000089A/es unknown
- 2011-01-11 CO CO11002068A patent/CO6341556A2/es active IP Right Grant
- 2011-01-11 CR CR20110021A patent/CR20110021A/es unknown
- 2011-01-11 IL IL210554A patent/IL210554A0/en not_active IP Right Cessation
- 2011-01-11 ZA ZA2011/00287A patent/ZA201100287B/en unknown
- 2011-02-08 MA MA33588A patent/MA32542B1/fr unknown
- 2011-12-07 HK HK11113241.7A patent/HK1158547A1/xx not_active IP Right Cessation
-
2012
- 2012-07-10 CY CY20121100615T patent/CY1112900T1/el unknown
- 2012-08-27 HR HRP20120678AT patent/HRP20120678T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2871027T3 (es) | Inhibidores potentes de la epóxido hidrolasa soluble | |
| JP6120951B2 (ja) | 新規ｅｐ２受容体作動薬 | |
| JP2016532677A5 (es) | ||
| AR072734A1 (es) | Composiciones farmaceuticas basadas en antagonistas del receptor de quinina b2 y corticosteroides y su uso | |
| AR097078A1 (es) | Combinaciones que comprenden compuestos maba y corticosteroides, uso, kit y compuesto | |
| NZ600637A (en) | Pyrazole compounds as crth2 antagonists | |
| EA200601880A1 (ru) | Замещенные производные 4-алкил- и 4-алканоилпиперидина и их применение в качестве антагонистов нейрокининов | |
| JP6620171B2 (ja) | 新規縮環フェノキシアセトアミド | |
| CO6170341A2 (es) | Formulacion de aerosol que contiene derivados de benzoxazin-3onas | |
| EP3603640A1 (en) | Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses | |
| RU2018103940A (ru) | Фармацевтические композиции, содержащие антагонист интегрина альфа4, для применения в лечении воспалительных состояний глаза | |
| WO2020093097A1 (en) | Compounds and compositions for the treatment of respiratory diseases | |
| CA2726074C (en) | Composition comprising an antibiotic and a corticosteroid | |
| JP2012501315A (ja) | 鼻炎を治療するためのｔｒｐｖｌアンタゴニストｓｂ−７０５４９８ | |
| JP2015522544A5 (es) | ||
| JP4559703B2 (ja) | チオトロピウム塩を含有する溶液の吸入組成物 | |
| MX2013013879A (es) | Formulacionn farmaceutica nasal que comprende fluticasona. | |
| JP2013538867A (ja) | 新規組合せ剤 | |
| JP2011153136A (ja) | ビフェニル−２−イル−カルバミン酸１−｛９−［（３−フルオロ−４−ヒドロキシ−ベンゾイル）−メチル−アミノ］−ノニル｝−ピペリジン−４−イルエステル塩酸塩 | |
| ATE478075T1 (de) | Diazaspiro-ä4,4ü-nonanderivate als neurokinin- (nk1)-antagonisten | |
| RU2014122958A (ru) | Офтальмологическая композиция, обладающая противовоспалительным и противоаллергическим действием, для лечения конъюктивитов и блефаритов при местном применении | |
| TH96111A (th) | พหุสัณฐานของ (r)-3-(2-ไฮดรอกซี-2,2-ไดเฟนิล-อะเซท็อกซี)-1-(ไอช็อกซาโซล-3-อิลคาร์บาโมอิล-เมทิล)-1-เอโซเนีย-ไบไซโคล-[2.2.2]ออกเทน โบรไมด์ | |
| BR102014031236A2 (pt) | composição farmacêutica de desloratadina e prednisolona | |
| TH96111B (th) | พหุสัณฐาน (r)-3-(2-ไฮดรอกซีซี-2,2-ไดเฟนิล-อะเซท็อกซี)-1-(ไอช็อกซาโชล-3-อิลคาร์บาโมอิล-เมทิล)-1-เอโชเนี่ย-ไบไซโคล-[2.2.2]ออกเทน โบรไมต์ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |